Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-27T23:47:37.064Z Has data issue: false hasContentIssue false
  • English
  • Français

Global Rating, Symptoms, Behavior, and Cognitive Performance as Indicators of Efficacy in Clinical Studies with Nimodipine in Elderly Patients with Cognitive Impairment Syndromes

Published online by Cambridge University Press:  07 January 2005

N. Schmage  and
M. Bergener
N. Schmage
Affiliation:
Bayer AG, Institute of Clinical Research D, Pharma Research Center, Wuppertal, Germany
M. Bergener
Affiliation:
Heinrich-Heine-Universität, Faculty of Medicine, Düsseldorf, Germany
Get access

Abstract

Nimodipine is a calcium antagonist which improves learning and memory in brain-lesioned or aged animals (LeVere & Sandin, 1989; Schuurman & Traber, 1989). It also accelerates the recovery of experimentally damaged sciatic nerves (van der Zee et al., 1987) and reduces age-associated gait abnormalities in aging rats (Schuurman et al., 1987). Selective action on cerebral vessels has also been proven. Vasoconstriction was prevented or reduced with nimodipine under experimental conditions (Toward, 1981) and cerebral blood flow could be increased (Kazda et al., 1982). The drug has been tested in subarachnoid hemorrhage, stroke, severe head injury, cerebral resuscitation after cardiac arrest, impaired brain function in old age, and dementia. Methodological aspects of clinical studies with this agent are examined in this paper.

Type
Research Article
Information
International Psychogeriatrics , Volume 4 , Issue 3 , April 1992 , pp. 89 - 99
Copyright
© 1992 Springer Publishing Company

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)